SCI-110 for Alzheimer Disease and Agitation

Inclusion Criteria: * Male or female aged \>60 to \<85 years inclusive. * Patients diagnosed according to the NINCDS criteria for AD (possible and probable). * MMSE less than 24 at the time of screening. * Patients who in the opinion of the investigators need medication to control agitation or whose current anti-agitation medication is ineffective or poorly tolerated * Patients who have been taking stable dose concomitant medications for at least 1 week. * Only individuals who have a legally appointed guardian who can sign Informed Consent Form (ICF) Exclusion Criteria: * Participant in other clinical trial during the last 30 days. * Any disorder which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol. * Patients whose agitation can be attributed to a somatic disorder (Ex. urinary tract infection or urinary retention) * Patient with uncontrolled congestive heart failure. * Patients who get the following medications: opiates, Primidone, Phenobarbitol, carbamazepine, Rifampicin, Rifabutin, Troglitazone and Hypericum perforatum. * Male patients who in the opinion of the investigator are at risk of urinary retention due to the anticholinergic proprieties of THC * Subjects with known sensitivity to the active substance dronabinol or to any of the components of the drug (sesame oil, gelatin, glycerol, titanium dioxide * Subjects that previously suffered from cannabinoids' related adverse effects. * Subjects with a history of diagnosed Mental or Psychiatric diseases * Patients who in the opinion of the investigator are at risk of falling beyond the risk associated with AD (example: postural hypotension, unstable blood pressure, with or without administration of anti-hypertensive medication, α1 blocker drugs used to treat benign prostatic hyperplasia * Patients diagnosed with epilepsy